Angina Pectoris Drugs Market Analysis, By Therapeutic Class (Beta Blockers, Calcium Antagonists, Anticoagulants, Antiplatelet, Nitrates, ACE inhibitors, Ranolazine), By Major Markets, And Segment Forecasts, 2016 - 2022

Report Overview

The global angina pectoris drugs market size was valued at USD 8.5 Billion in 2016 and is expected to grow at a CAGR of 3.2% during the forecast period. The U.S. dominated the angina pectoris drugs market among the seven major countries. The global angina pectoris market is expected to be collectively driven by demand for disease-modifying and targeted treatments, increased expenditure on healthcare, and availability of effective treatment methods across the emerging markets.

Angina pectoris is a clinical indication characterized by precordial heaviness or discomfort due to transient myocardial ischemia without infarction, elicited by physical exertion or psychological stress. Angina pectoris is categorized as - stable, unstable, microvascular, and Prinzmetal / variant. Angina pectoris is an initial presentation of coronary heart disease (CHD) and exerts a major impact on quality of life (QOL), costs to the society, and ability to work. 

Chronic stable angina pectoris has a prevalence of 2.0 - 4.0% in the seven major markets (U.S., U.K., Germany, France, Italy, Spain, Japan). Heart Disease and Stroke Statistics from the American Heart Association estimates indicate that over nine million adults in the U.S. have chronic angina pectoris. We estimate the annual risk of associated non-fatal myocardial infarction (MI) and death at 3% and 1.0-2.0% respectively. The prevalence of angina rises sharply with age in both genders, ranging from 2.0- 5.0% in men aged 45-54 to 10.0-20.0% in men aged 65-74 and from 0.1- 1.0% in women aged 45-54 to 10.0-15.0% in women aged 65-74.

Therapeutic Class Insights

The angina pectoris drug market is commercially meaningful, however, branded sales are in decline as generics dominate a larger portion of prescriptions. Though the market is fragmented, key players such as Sanofi, Gilead, AstraZeneca, and Pfizer hold significant market positions. Rising geriatric population in territories such as China will influence the demand for angina pectoris drugs in the coming years.

The drug space can be divided into various therapeutic classes such as Beta Blockers, Calcium Antagonists, Anti-Platelets, Anticoagulants, Nitrates, and Ranolazine. The Beta-Blocker market now is predominately generic with key patent expirations impacting GlaxoSmithKline’s Coreg and AstraZeneca’s Toprol. Post Pfizer’s Norvasc patent being determined invalid in 2007, the Calcium Antagonist market is predominantly generic as well.

Pipeline Insights

Novel targets and therapies gaining traction include Factor Xa Inhibitors, monoclonal antibodies, and gene therapy. Some prominent players covered in the segment include Amgen, Taxus Cardium Pharmaceuticals, LegoChem Biosciences, Lee’s Pharmaceutical Holdings, Milestone Pharmaceuticals, Juventas Therapeutics, ViroMed, and Kuhnil Pharmaceutical.

Changing regulatory scenario in the U.S. and EU is anticipated to impact clinical trials of Advanced Therapy Medicinal Products. Multiple gene therapy products in Phase II/III trials are emerging as a novel approach towards addressing the need for non-surgical cardiovascular treatments. Taxus Cardium’s adenovector (serotype 5) DNA-based gene therapy is undergoing late-stage clinical trials and could present promising growth opportunities for the market in the next few years.

Regional Insights

The U.S. dominated the space by accounting for more than 33.0% of the market share in 2016. Established healthcare infrastructure, increased adoption of therapeutics, and presence of key manufacturers in the U.S. are responsible for its large share. Moreover, increasing incidence of cardiac disorders due to sedentary lifestyle and favorable regulatory initiatives are fueling the market growth.

China offers strong opportunity for market expansion due to removal of price caps on all medicine categories, the ongoing Healthy China 2020 healthcare reform, and supportive 12th Five-Year Plan measures that target biotechnology as key development sector. Furthermore, presence of a large target population and strong unmet clinical needs are some of the factors that are expected to propel the growth of this region.

Competitive Insights

Some of the key players operating in this industry are Sanofi, Gilead, AstraZeneca, Pfizer, Eli Lilly, Amgen, and GlaxoSmithKline. The companies are focusing on business expansion in emerging markets or developing regions such as China by adopting strategies including mergers & acquisitions for the development of new products.

Biosimilar development is emerging as a promising market opportunity in angina therapeutics. Multiple enoxaparin sodium and abciximab biosimilars have gained approvals in the U.S., European and Indian markets.

Angina Pectoris Drugs Market Report Scope

Segments Covered in the Report

This report provides an analysis of the market trends in each sub-category as well as forecasts revenue growth from 2014 to 2022. For this study, Grand View Research has segmented the angina therapeutics market based on therapeutic class:

• Therapeutic Class Outlook (% market share; 2016 - 2022)

  • Beta Blockers

  • Calcium Antagonists

  • Anticoagulants

  • Anti-Platelets

  • Others

    • Nitrates

    • Anti-anginal (Ranolazine)

    • ACE inhibitors

• Regional Outlook (% market share; 2016 - 2022)

  • The U.S.

  • U.K.

  • France

  • Germany

  • Italy

  • Spain

  • Japan